ArticleInternational journal of toxicology

An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics.

Jennifer D Sisler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.